- has received (1) a sars-cov-2 vaccine, (2) mab or (3) convalescent plasma from a person who has recovered from covid-19 or prior participation in sars-cov2 vaccine, convalescent plasma, or mab clinical trial any time prior to participation in the study. - receipt of any investigational product within 30 days or 5 half lives before the day of enrollment. - is acutely ill or febrile 72 hours before or at screening or has other covid-19 symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or smell. fever is defined as a body temperature ≥38.0°c (≥100.4°f). - has received or plans to receive a non-covid-19 vaccine within 28 days before or after dosing (except for seasonal influenza vaccine, which is not permitted within 14 days before or after dosing). note: other protocol defined inclusion/exclusion criteria apply

- has received (1) a sars-cov-2 vaccine, (2) mab or (3) convalescent plasma from a person who has recovered from covid-19 or prior participation in sars-cov2 vaccine, convalescent plasma, or mab clinical trial any time prior to participation in the study. - receipt of any investigational product within 30 days or 5 half lives before the day of enrollment. - is acutely ill or febrile 72 hours before or at screening or has other covid-19 symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or smell. fever is defined as a body temperature ≥38.0°c (≥100.4°f). - has received or plans to receive a non-covid-19 vaccine within 28 days before or after dosing (except for seasonal influenza vaccine, which is not permitted within 14 days before or after dosing). note: other protocol defined inclusion/exclusion criteria apply